CytoMed Therapeutics Limited Ordinary Shares

CytoMed Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing novel cell-based immunotherapies for human cancers and degenerative diseases in Malaysia and Singapore. Its lead candidate, CTM-N2D, consists of expanded gamma delta T cells engineered with a natural killer group 2D ligand-targeting chimeric antigen receptor and is in Phase I trials to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cell platform; CTM-GDT, an allogeneic gamma delta T cell product candidate; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cell therapy for cartilage injury. It has a research collaboration with Sengkang General Hospital for in vivo studies and a Phase I trial of CTM-MSC in Singapore, and a business and research collaboration with SunAct Cancer Institute Private Limited for clinical trials of GMP-grade CTM-GDT. Incorporated in 2018, CytoMed Therapeutics is headquartered in Singapore.